MR Imaging of the Brain in Neurologic Wilson Disease

References

1. 1.↵
   2. Bandmann O,
   3. Weiss KH,
   4. Kaler SG

   . Wilson's disease and other neurological copper disorders. Lancet Neurol 2015;14:103–13 doi:10.1016/S1474-4422(14)70190-5 pmid:25496901

   CrossRefPubMed
2. 2.↵
   2. Ferenci P

   . Pathophysiology and clinical features of Wilson disease. Metab Brain Dis 2004;19:229–39 doi:10.1023/B:MEBR.0000043973.10494.85 pmid:15554419

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Gromadzka G,
   3. Schmidt HH,
   4. Genschel J, et al

   . p.H1069Q mutation in ATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson's disease. Mov Disord 2006;21:245–48 doi:10.1002/mds.20671 pmid:16211609

   CrossRefPubMed
4. 4.↵
   2. Thomas GR,
   3. Forbes JR,
   4. Roberts EA, et al

   . The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet 1995;9:210–17 doi:10.1038/ng0295-210 pmid:7626145

   CrossRefPubMedWeb of Science
5. 5.↵
   2. Zong Y,
   3. Kong X

   . Mutation analysis of 35 Wilson's disease pedigrees [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2016;33:30–33 doi:10.3760/cma.j.issn.1003-9406.2016.01.008 pmid:26829729

   CrossRefPubMed
6. 6.↵
   2. Schilsky ML

   . Wilson disease: diagnosis, treatment, and follow-up. Clin Liver Dis 2017;21:755–67 doi:10.1016/j.cld.2017.06.011 pmid:28987261

   CrossRefPubMed
7. 7.↵
   2. Yang RM

   . Hepatolenticular Degeneration. Beijing: People's Medical Publishing House; 2015
8. 8.↵
   2. Yu XE,
   3. Yang RM

   . 132 cases brain imaging of hepatolenticular degeneration. J Apopl Nerv Dis 2007;1:30–34
9. 9.↵
   2. Litwin T,
   3. Dus˘ek P,
   4. Czlonkowska A

   . Symptomatic treatment of neurologic symptoms in Wilson disease. Handb Clin Neurol 2017;142:211–23 doi:10.1016/B978-0-444-63625-6.00018-5 pmid:28433105

   CrossRefPubMed
10. 10.↵
    2. Litwin T,
    3. Dziez̊yc K,
    4. Karliński M, et al

    . Early neurological worsening in patients with Wilson's disease. J Neurol Sci 2015;355:162–67 doi:10.1016/j.jns.2015.06.010 pmid:26071888

    CrossRefPubMed
11. 11.↵
    2. Lorincz MT

    . Neurologic Wilson's disease. Ann N Y Acad Sci 2010;1184:173–87 doi:10.1111/j.1749-6632.2009.05109.x pmid:20146697

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Lucato LT,
    3. Otaduy MC,
    4. Barbosa ER, et al

    . Proton MR spectroscopy in Wilson disease: analysis of 36 cases. AJNR Am J Neuroradiol 2005;26:1066–71 pmid:15891161

    Abstract/FREE Full Text
13. 13.↵
    2. van Wassenaer-van Hall HN,
    3. van den Heuvel AG,
    4. Algra A, et al

    . Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. Radiology 1996;198:531–36 doi:10.1148/radiology.198.2.8596862 pmid:8596862

    CrossRefPubMedWeb of Science
14. 14.↵
    2. Ranjan A,
    3. Kalita J,
    4. Kumar S, et al

    . A study of MRI changes in Wilson disease and its correlation with clinical features and outcome. Clin Neurol Neurosurg 2015;138:31–36 doi:10.1016/j.clineuro.2015.07.013 pmid:26278999

    CrossRefPubMed
15. 15.↵
    2. Kalita J,
    3. Naik S,
    4. Bhoi SK, et al

    . Pontomesencephalic atrophy and postural instability in Wilson disease. AJNR Am J Neuroradiol 2017;38:1343–47 doi:10.3174/ajnr.A5207 pmid:28495941

    Abstract/FREE Full Text
16. 16.↵
    2. Yu XE,
    3. Hu WB,
    4. Han YZ, et al

    . The regionalism of Wilson disease in Anhui Province. Chin J Nerv Ment Dis 2012;38:435–38
17. 17.↵
    2. Das M,
    3. Misra UK,
    4. Kalita J

    . A study of clinical, MRI and multimodality evoked potentials in neurologic Wilson disease. Eur J Neurol 2007;14:498–504 doi:10.1111/j.1468-1331.2006.01676.x pmid:17437607

    CrossRefPubMed
18. 18.↵
    2. Kim S,
    3. Song IU,
    4. Chung YA, et al

    . Brain MRI, Tc-99m HMPAO SPECT and F-18 FP-CIT PET/CT findings in a patient with Wilson disease: a case report. Nucl Med Mol Imaging 2014;48:303–05 doi:10.1007/s13139-014-0290-4 pmid:26396635

    CrossRefPubMed
19. 19.↵
    2. Park HK,
    3. Lee JH,
    4. Lee MC, et al

    . Teaching NeuroImages: MRI reversal in Wilson disease with trientine treatment. Neurology 2010;74:e72 doi:10.1212/WNL.0b013e3181dad5cc pmid:20421574

    FREE Full Text
20. 20.↵
    Chinese Medical Association Neurology Branch. A guide to diagnosis and treatment of hepatolenticular degeneration. Chin J Neurol 2008;41:566–69
21. 21.↵
    2. Roberts EA,
    3. Schilsky ML

    . Diagnosis and treatment of Wilson disease: an update. Hepatology 2008;47:2089–111 doi:10.1002/hep.22261 pmid:18506894

    CrossRefPubMedWeb of Science
22. 22.↵
    European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 2012;56:671–85 doi:10.1016/j.jhep.2011.11.007 pmid:22340672

    CrossRefPubMed
23. 23.↵
    2. King AD,
    3. Walshe JM,
    4. Kendall BE, et al

    . Cranial MR imaging in Wilson's disease. AJR Am J Roentgenol 1996;167:1579–84 doi:10.2214/ajr.167.6.8956601 pmid:8956601

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Thuomas KA,
    3. Aquilonius SM,
    4. Bergström K, et al

    . Magnetic resonance imaging of the brain in Wilson's disease. Neuroradiology 1993;35:134–41 doi:10.1007/BF00593970 pmid:8433789

    CrossRefPubMed
25. 25.↵
    2. Scheiber IF,
    3. Brůha R,
    4. Dus˘ek P

    . Pathogenesis of Wilson disease. Handb Clin Neurol 2017;142:43–55 doi:10.1016/B978-0-444-63625-6.00005-7 pmid:28433109

    CrossRefPubMed
26. 26.↵
    2. Prayer L,
    3. Wimberger D,
    4. Kramer J, et al

    . Cranial MRI in Wilson's disease. Neuroradiology 1990;32:211–14 doi:10.1007/BF00589114 pmid:2215906

    CrossRefPubMed
27. 27.↵
    2. Burke JF,
    3. Dayalu P,
    4. Nan B, et al

    . Prognostic significance of neurologic examination findings in Wilson disease. Parkinsonism Relat Disord 2011;17:551–56 doi:10.1016/j.parkreldis.2011.05.002 pmid:21641265

    CrossRefPubMed
28. 28.↵
    2. Dusek P,
    3. Litwin T,
    4. Czlonkowska A

    . Wilson disease and other neurodegenerations with metal accumulations. Neurol Clin 2015;33:175–204 doi:10.1016/j.ncl.2014.09.006 pmid:25432729

    CrossRefPubMed
29. 29.↵
    2. Thenganatt MA,
    3. Jankovic J

    . Treatment of dystonia. Neurotherapeutics 2014;11:139–52 doi:10.1007/s13311-013-0231-4 pmid:24142590

    CrossRefPubMed
30. 30.↵
    2. Oder W,
    3. Brücke T,
    4. Kollegger H, et al

    . Dopamine D2 receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal 123I-iodobenzamide binding. J Neural Transm (Vienna) 1996;103:1093–103 doi:10.1007/BF01291794 pmid:9013397

    CrossRefPubMed
31. 31.↵
    2. Puschmann A,
    3. Wszolek ZK

    . Diagnosis and treatment of common forms of tremor. Semin Neurol 2011;31:65–77 doi:10.1055/s-0031-1271312 pmid:21321834

    CrossRefPubMed
32. 32.↵
    2. Schneider SA,
    3. Deuschl G

    . The treatment of tremor. Neurotherapeutics 2014;11:128–38 doi:10.1007/s13311-013-0230-5 pmid:24142589

    CrossRefPubMed
33. 33.↵
    2. Yu XE,
    3. Hu WB,
    4. Han YZ, et al

    . The course and prognosis of Wilson's disease. Chin J Neurol 2012;45